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Abbreviations list  
COPD:         Chronic Obstructive Pulmonary Disease 
EMT:            Epithelial Mesenchymal Transition 
GOLD:         Global Initiative for Chronic Obstructive Lung Disease 
TGF:            Transforming Growth Factor 
FEV1:            Forced Expiratory Volume in 1 second  
FVC:             Forced Vital Capacity 
Rbm:             Reticular Basement Membrane 
LP:                Lamina Propria 
ECM:            Extra Cellular Matrix 
TNF:             Tumor necrosis Factor  
IFN:               Interferon 
H-N:              Healthy Non Smoker 
NLFS:           Normal lung function smoker 
S-COPD:      Smoking COPD 
ES-COPD:   Ex-Smoker COPD 
 
Summary at glance 
COPD is fundamentally due to small airway fibrosis in association with exposure to 
cigarette smoke. Pathologically, it is associated with active EMT whereby epithelial cells 
develop mesenchymal phenotype and become invasive. Relatively little has been 
known regarding the association of the TGFβ1-pSmad pathway with EMT in smokers 
and COPD. This study facilitates the understanding of EMT-associated pathogenesis of 
COPD as a result of smoking induced intracellular downstream Smad transcriptional 
pathways.
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Abstract 
Background: COPD is characterised by poorly reversible airflow obstruction usually 
due to cigarette smoking. TGFβ1 has been implicated in the pathogenesis of COPD, 
and in particular a process called epithelial mesenchymal transition (EMT), which 
may well be an intermediatory between smoking and both airway fibrosis and lung 
cancer. The downstream classical or “canonical” TGFβ1 pathway is via the 
phosphorylated (p) Smad transcription factor system. 
 
Methods: We have investigated TGFβ1 expression and its “pSmad fingerprint” in 
bronchoscopic airway biopsies from patients with COPD, and in smoking and non-
smoking controls. A cross sectional immunohistochemical study compared TGFβ1 
and pSmad 2, 3 (excitatory) and 7 (inhibitory) expression in cells and blood vessels 
of 3 compartments of large airways: epithelium (especially the basal region), reticular 
basement membrane (Rbm) and underlying lamina propria (LP). 
 
Results: TGFβ1 expression was higher generally in COPD subjects throughout the 
airway wall (P<0.01), while pSmad 2/3 expression was associated with smoking but 
especially current smoking COPD (P<0.05). Expression of inhibitory pSmad-7 was 
also prominently reduced in patients with COPD in contrast to smokers and controls 
(P<0.01). In addition, pSmad but not TGFβ1 expression, was related to airflow 
obstruction and a canonical EMT biomarker (S100 A4) expression. 
 
Conclusion: Activation of the Smad pathway in the airways is linked to EMT activity 
and loss of lung function. The disconnect between TGFβ1 and pSmad in terms of 
relationships to EMT activity and lung function, suggests that factors other or in 
addition to TGFβ1 are driving the process. 
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Introduction 
Chronic obstructive pulmonary disease (1) is a poorly reversible chronic, slowly 
progressive airway obstructive respiratory disease It is mainly smoking-related and 
primarily constitutes small airway fibrosis and destruction, more generalized “chronic 
bronchitis” and in some but not all later development of emphysema. Approximately 
50% of smokers develop COPD eventually (2, 3). 
 
Smoking is associated with airway luminal innate inflammation but the change within 
the airway wall in susceptible individuals are more characterized by tissue 
remodelling. TGFβ1 is a multifunctional cytokine which induces a number of 
biological processes including regulation of angiogenesis and ECM components and 
has been implicated as a driver of COPD airway pathology (2, 4, 5). The best 
described intracellular pathway for TGFβ1 actions is the so called “canonical” 
cascade involving up-regulation and phosphorylation of Smad 2/3 (5, 6); one 
outcome of this is activation of a process called Epithelial-mesenchymal Transition 
(EMT) (7), which we have described as active in COPD (8, 9). 
 
Smads are transcription factors (10), including stimulatory, receptor-activated Smads 
1, 2, 3,5, 8 and 9; (11), a common co-mediator Smad4 (12) and inhibitory Smads 6 
and 7; (13). Binding of TGF-β1 to its Type II receptor leads to formation of a receptor 
complex that phosphorylates the Smad-2/3 complex, which in turn interacts with a 
transporter Smad 4 for translocation to the nucleus. In the nucleus, the pSmad 
complex binds to a specific promotor region of target genes (14) (Fig-1). Inhibitory 
Smads act as an important brake on TGF-β1 signaling by binding stably to TGF-β1 
receptors and/or by competing for the common mediator Smad4 (10). Smad 7 is 
activated (phosphorylated) by proinflammatory cytokines TNF-α and IFN-γ but is 
Page 5 of 43
Editorial Office: respirology-aphb@uwa.edu.au; Editor-in-Chief: Prof Peter R. Eastwood
Respirology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL for peer review only
 6
transcriptionally regulated by TGF-β1 itself, as well as Epidermal Growth Factor 
(EGF) and ultraviolet radiation (15) . Springer and colleagues previously 
demonstrated reduced Smad 7 gene expression in bronchial biopsies of COPD 
patients (16), suggesting that lack of Smad 7 could be relevant to pathogenesis (17)  
 
A preliminary study from our group suggested that TGFβ1 was indeed functionally 
active through pSmad 2/3 expression in COPD (18). The present study has taken 
this further and evaluated TGFβ1 expression and its associated downstream “Smad 
fingerprint” in airway biopsy material from COPD subjects and appropriate smoking 
and non-smoking controls. We hypothesized that: 1) TGFβ1 and pSmad 2/3 
expression is increased in smokers but especially in COPD subjects, 2) pSmad 7’s 
protective role is down regulated in a reciprocal way to Smad 2/3 activation. 3) There 
may be a relationship between activation of the TGFβ1 pathway and EMT and airflow 
obstruction. 
 
MATERIALS AND METHODS 
Ethics approval 
The Tasmania Health & Medical Human Research Ethics Committee approved the 
study (EC00337). All subjects gave written, informed consent prior to participation. 
Subjects 
64 subjects were recruited through advertisement. Bronchial biopsies (BB) from 15 
smokers with normal lung function (S-N), 17 S-COPD and 17 ES-COPD were 
compared with 15 H-N (Table 1). COPD was diagnosed according to GOLD criteria 
(1). Subjects with other respiratory diseases, a history of recent acute exacerbation 
of COPD were excluded from the study. COPD subjects were on PRN (as needed) 
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bronchodilators for the most part, and especially none were using systemic or 
inhaled corticosteroids. 
 
Tissue Processing 
Biopsies were first fixed in 10% neutral buffered formalin for 2 hrs. then in 50% 
ethanol before processing on a Leica ASP 200 tissue processor. Paraffin embedded 
sections of 3mm were cut for staining, separated by at least 50 microns and 
mounted on slides. 
After removal of paraffin, sections were stained with either monoclonal antibody anti-
TGFβ1 (abcam ab 27969 clone TB1 at 1/16000 26 mg/ml- overnight at room 
temperature) after blocking with Dako serum block (X0909), phosphorylated 
(activated) Smad2/3 (pSmad2/3) (Santa Cruz SC-11769R at 1:100 for 1hour at room 
temperature) following heat retrieval using a Dako PT link with high pH solution 
K800421 at 95 degrees for 30 minutes and pSmad 7((Santa Cruz SC-101152 at 
1:100 for 60 minutes at room temperature) In each run a section stained with 
immunoglobulin (Ig) G1-negative control (X0931 clone DAKGO1; Dako Cytomation) 
was included to ensure absence of false positive staining and a known lung tissue 
positive tissue control was run with each staining. Bound antibodies were elaborated 
by using horseradish peroxidase (HRP) conjugated DAKO Envision plus reagent (cat 
no. K4001, anti-mouse or K4003 anti-rabbit) and diaminobenzidine (DAB) for a 
brown colour resolution (cat. no. K3468; Dako Cytomation). Nuclei were 
counterstained using Mayers Haematoxylin and sections dehydrated through 
ascending grades of ethanol, cleared in xylene and mounted in permount. We have 
extensively used and published with these methods (8, 19)  
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Tissue section analysis and quantitation 
All slides were coded and randomized to blind the person who did the 
measurements (MM). We randomly choose five good fields for measurement from 
each slide, for each of the biomarkers. Only areas with intact epithelium and LP and 
without tissue damage were selected for measurement. Measurements were 
performed by computer-assisted image analysis using microscopy at 40x 
magnification (Leica DM 2500, Microsystems, Germany), a Spot insight 12 digital 
camera (Spot imaging, USA) and Image Pro V5.1 software (Media Cybernetics, 
USA). 
All biomarkers (TGFβ1, pSmad 2/3, pSmad 7) were quantitated as percentage of 
epithelial area so stained, as number stained basal epithelial cells, as well as cells 
and vessels stained in the Rbm per mm of Rbm. In addition, pSmad 2/3 and pSmad 
7 immuno-staining were also quantified in LP cells and LP vessels as % of total cells 
and vessels. 
 
Statistical analysis  
Since the data were non-normally distributed, the results for each marker are 
presented as the median and range. Non-parametric ANOVA (Kruskal-Wallis) was 
first used to detect any overall difference among study groups, followed by Dunn’s 
multiple comparison test to specify which groups were different. Finally, the Mann-
Whitney U test used to confirmed statistical difference between groups. This method 
minimized multiple comparisons but appropriate correction was made to each P 
value where these were done. Statistical analyses were performed using SPSS 
(statistics version 20.0, IBM Co, USA) for Windows 7.0 and a p-value of ≤ 0.05 was 
considered statistically significant. 
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RESULTS  
 
TGFβ1 expression (Fig 2&3) 
Epithelium  
A greater proportion of the cells in the basal layer of the large airway epithelium 
stained for TGFβ1 in NLFS, S-COPD and ES-COPD in comparison to H-N control 
group (p<0.05), but with no significant difference between smoker/ COPD groups. 
 
Rbm: 
Rbm cells highly expressed TGFβ1 in NLFS, S-COPD, and ES-COPD in comparison 
to H-N control group (P<0.005), but this was most marked in S-COPD i.e. there was 
both a smoking and extra COPD effect (P<0.005).  
 
TGFβ1 expression on blood vessels in the Rbm was significantly increased in all 
smoker/COPD groups (p<0.05). The data were also analysed as percent of vessels 
that stained, since vessels numbers are markedly increase in this compartment in 
smokers/COPD groups. (20) The message was much the same when plotted as 
percentages. 
 
LP: 
There was either no or just light staining in a diffuse pattern in the normal controls 
throughout the LP, which was very much heavier, and uniformly so, in all 
smoker/COPD groups. This was not possible to quantify precisely. 
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pSmad 2/3 expression: (Fig 4&5) 
Epithelium: 
Compared to normal control (H-N), there was an increased proportion of cells in the 
basal area staining for pSmad 2/3 expression in smoking groups (both NLFS and S-
COPD) (P<0.05) but not in the ES-COPD group. 
 
Rbm: 
There was significantly increased expression of pSmad 2/3 in NLFS but especially in 
S-COPD. An elevated expression of pSmad 2/3 in Rbm cells in the ES-COPD group 
was intermediate between controls and the other pathological groups. i.e. there was 
predominantly a smoking effect but again some extra COPD effect. 
 
Similarly, pSmad 2/3 vessel expression was greater in the NLFS and S-COPD 
groups, but not in the ES-COPD group. When these data were examined in terms of 
percent vessels, to take into account between-group variations, the outstanding 
feature was a marked increase in the S-COPD group. 
 
LP:  
In LP cells there was an increase pSmad 2/3 expression only in the COPD groups, 
perhaps a little more marked in S-COPD (P<0.001). Total cell number in the LP are 
decreased in COPD, so data were analysed as percentage of cells expressing 
pSmad 2/3; percent cell staining was especially marked in the S-COPD group. 
 
In the LP vessels, there was an increase in pSmad 2/3 expression in both smoking 
groups, but again especially so in current smoking COPD (S-COPD) (P<0.005). 
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pSmad 7 expression (Fig 6&7): 
In general, pSmad 7 expression was inverse of that for pSmad 2/3, but not always. 
 
Epithelium: 
In contrast to pSmad 2/3, pSmad 7 stained cells in the basal area of the epithelium, 
was slightly increased in NLFS (P<0.01) but slightly reduced though unchanged in 
the COPD groups.  
 
Rbm: 
There was little change in Rbm cell expression of pSmad 7, with just a slight 
increasing in NLFS and again a slight decrease in COPD.  
The pattern in Rbm vessels was similar; through the decrease in percent vessel 
staining in S-COPD was much more marked. 
 
LP: 
In absolute numbers, there was a reduction in pSmad 7 cell expression in smokers 
and COPD about equally.  
 
In LP vessels, there was a decrease in pSmad 7 expression in NLFS which was 
more marked and significant in COPD groups. In percentage terms, taking into 
account a reduction in vessels in COPD LP, the pattern was similar but with a more 
marked decrease in ES-COPD, and little change in normal lung function smokers i.e. 
more of a COPD-only effect. 
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pSmad 2/3:7 ratios for cellular expression (Fig 8) 
In the epithelium, there was a significant increase in this ratio only in current smoker 
COPD (S-COPD) subjects.  
 
In the Rbm there was a large increase in pSmad 2/3 to 7 ratio in both COPD groups. 
Finally, in LP cells there was again a marked increase in the ratio in both COPD 
groups (<0.001).  
 
Regression Data (Fig 9 & 10) 
 
A) pSmads basal cell expression versus lung function: 
Right across the board, whether looking at FEV1, FEV1/FVC ratio (FER), or FEF25-75 
% (small airways), there were remarkably consistent negative relationships in all 
smokers/COPD groups with pSmad 2/3 cell expression, and positive relationships 
with pSmad 7 expression. This is illustrated for ES-COPD in figure 9. This group was 
chosen for presentation since it is less likely confounded by potential co-existing 
effects of active smoking in addition to COPD, though each pathological group data 
were very similar. 
 
B) Basal cell pSmads expression versus basal cell S100A4 (EMT bio-marker):  
In order to elaborate the relationship between expression of these Smad 
transcriptional pathways and EMT, cellular expression of both pSmad 2/3 and 
pSmad 7 were correlated with the classical EMT mesenchymal marker S100A4 (8). 
Again, there were consistent relationships between epithelial basal cell and Rbm cell 
expression of pSmad 2/3 (positive) and pSmad 7 (negative) with S100A4. Similarly 
Page 12 of 43
Editorial Office: respirology-aphb@uwa.edu.au; Editor-in-Chief: Prof Peter R. Eastwood
Respirology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL for peer review only
 13
the pSmad 2/3:7 ratio also had consistently positive relationships with the EMT 
marker (Fig-10, with ES-COPD as the exemplar). 
 
C) Basal cells TGFβ1 expression against pSmads and S100A4 expression and 
lung function: 
In contrast, there were no significant relationships shown in either of these 
regression analyses. 
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DISCUSSION 
 
COPD is a potentially complex condition, but the basic pathophysiology at least in 
early disease is fibrosis and destruction of small airways (21). However, we do not 
understand why this process occurs apart from smoking being a driver of it. Thus, 
although COPD is usually described as an abnormal inflammatory immune response 
to noxious particles and gases, how that actually translates into airway obstruction is 
not understood (22). There is now good evidence that there is dysregulated epithelial 
basal stem cell function (23), one feature of which is active EMT (8). TGFβ1 has been 
suggested as a key regulator of the fibrotic airway disease in COPD (24). Although 
considerable progress has been made in general in understanding TGFβ1 and 
associated intracellular downstream pathways, little is known about how TGFβ1 is 
involved in the pathology of COPD. However, cigarette smoke has been shown to 
induce TGFβ1 release by cultured mouse tracheal explants (25), although its down-
stream effectors, the activated transcription factors Smad 2/3 were reported not to be 
increased in expression in a histochemical study of small airways in COPD (26). The 
same authors did report downregulation of Smad 7 expression (26).  TGFβ1 has 
been postulated also as a key inducer of EMT in several tissues, including alveolar 
type II cells (27) in relation to idiopathic pulmonary fibrosis (IPF) (28), so some 
connection between TGFβ1, EMT and fibrosis is appearing in lung pathology. 
 
The activated receptor for TGFβ1 signals through phosphorylation of Smad 
transcription factors, known as its “canonical pathway”. However, as mentioned 
above it is not clear whether pSmads are active in the COPD airway wall or involved 
in inducing EMT or airflow obstruction in COPD. Ours is the first comprehensive 
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study to analyse the expression and assessment of the TGFβ1-related “classical” 
pathway transcriptional proteins in airway tissues from normal smokers and patients 
with COPD compared to normal controls. We have studied this in large airways 
because previous investigations have shown especially active EMT in this 
compartment, although a similar but less marked picture was also found in small 
airways (9). We have previously reported TGFβ1 expression to be increased in the 
epithelial Rbm of smokers and especially those with COPD (18) but then we focused 
only on the relationship of TGFβ1 to vascular structures. 
 
Our observation of an increase in TGFβ1 expression in basal cells of large airway 
epithelium in smokers is consistent with Takizawa and colleague’s observation that 
TGFβ1 expression is higher than normal in airway epithelial cells from COPD 
subjects and smokers (29). Similarly, De Boer at al found a small but significant 
increase in TGFβ1 expression is small airway epithelium from COPD patients (30), 
suggesting that our data may be generalizable to the whole airway tree. . In the 
current study the fact that cellular pSmad expression was closely associated in 
regressions with both EMT activity and airflow obstruction suggest strongly that this 
pathway is of functional significance in COPD pathogenesis. 
 
Several genetic studies have demonstrated a link between COPD and TGFβ1 in 
COPD (31). TGFβ1 can also induce EMT- type changes in respiratory epithelial cells 
(32). The epithelium in smokers is also likely to produce more TGF-β1, suggesting 
the possibility of a self-reinforcing vicious cycle to EMT stimulation (33). Our finding 
is novel in that we have shown both a general increase in TGFβ1 in all airway wall 
compartments studied, but a parallel change in downstream pSmad signalling. 
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These changes were also evident in both smokers and COPD generally, but more so 
in actively smoking COPD. It is in line with previous studies where anti TGFβ 
treatment was able to attenuate both airway pathology and emphysema in mice (34). 
 
In our work, although TGFβ1 expression was increased in the smoker/COPD 
airways, unlike pSmad there was no relationship to either EMT activity or obstructive 
lung function. This suggests that other growth factors or change in receptor 
responsiveness to TGFβ1 are involved. The Wnt-β catenin pathway has been 
previously described as a mediator in pulmonary fibrosis (35) and other signalling 
pathways such as Notch, nuclear factor-kB and Hedgehog (Hh) have been also 
shown to participate in EMT in some circumstances (36). Further work on these 
pathways in COPD needs to be done. 
 
Evidence of increased TGFβ1 expression by Rbm vessels was further supported by 
similar Rbm vascular expression of pSmad2/3 in smokers and COPD. Thus supports 
our previous suggestions that this system may be a driving factor for angiogenesis in 
the Rbm to produce the picture of Type-3 EMT we have described in large airways in 
COPD (9). Type-3 EMT is generally thought to be pre-malignant (37) A link between 
this process and malignancy is reinforced by the finding that EMT expression 
through a Smad-binding element is active in non-small cell lung carcinoma (38) 
where the TGFβ-Smad system also facilitates metastasis (39). It needs to be noted 
that lung cancer development is especially evident in smokers who have also 
developed COPD (40). 
 
The large majority of cells in the LP are thought to be stromal cells (41) and it is most 
likely that they are the one expressing Smad pathway activation. This would fit with 
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evidence that lung fibroblasts in COPD patients produce increased extracellular 
matrix (ECM), dependent on the local cytokine environment (42). 
 
One of the most remarkable findings in our current study was the significant 
correlation of pSmad 2/3 and pSmad 7 expression with both an EMT activity marker 
and airflow obstruction. This “mechanistic” relationship gives our findings relevance 
for the core COPD pathophysiology. Interestingly, in more advanced disease and in 
small airways, Zandevoort and colleagues did not find pSmad 2 expression in 
COPD; it may be that our study into earlier disease in COPD was more appropriate 
for investigating pathogenic mechanisms (26).  
 
The strengths of the present study include the use of relevant human tissue in very 
well phenotyped individuals with mild to moderate COPD, with fairly robust numbers 
giving sufficient power to detect these fascinating findings. This follows our previous 
work on EMT biomarker expression in both large and small airways. We have 
focused on mild to moderate COPD patients, because we wanted to look at 
pathogenic mechanisms in relatively early disease with relatively little confounding 
by chronic infection and emphysema. There are also a few limitations to this study. 
Firstly, it is cross-sectional at a single time point and longitudinal studies would be 
required to see how variable TGFβ1-pSmad expression is within individuals and if it 
relates to the natural history of smoker’s airway disease as it becomes more severe. 
Secondly, we are not yet sure about the true phenotype of the of LP cells expressing 
pSmad which will be a future goal. Finally, our control subjects were somewhat 
younger than the smoker/COPD group, but there was no evidence that this was a 
confounder as the growth factor and transcription factor expression levels were not 
age-related across any group.  
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Other future goals for research should include investigating other transcriptional 
pathways and proteins that could contribute potentially to driving EMT, including 
especially β-Catenin, Twist and Snail-1, and emphasising the process involved in 
small airways in comparison to large airways, the former being where the main 
destructive pathophysiology occurs.  
 
Conclusion & Summary: 
In conclusion, the TGFβ1-pSmad pathway is likely to be an important regulator of 
smoking-induced airway pathology including EMT, but also airway fibrosis leading to 
airway obstruction. The present study demonstrated a positive association between 
smoking, COPD and up regulation of stimulatory pSmads in all airway 
compartments, and in vessels as well as cells. The relationships seen between 
pSmad expression and EMT and also airflow obstruction supports these statements. 
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Table 1. Demographic detail and lung function data for participants 
 
 
Groups 
(numbers) 
 
NC 
(n=15) 
 
NLFS 
(n=15) 
S-COPD 
(n=17) 
ES-COPD 
(n=15) 
GOLD 
I/GOLD II‡ 
N/A N/A 10/7 8/7 
Male/female 7/8 11/4 9/8 9/6 
Age (years) 
44 (20-68) 
(p=0.313) 
50 (30-66) 
(p=0.313) 
61 (46-78) 
(p=0.001)* 
62 (53-69) 
(p=0.001)* 
Smoking 
(pack years) 
 
 
0 32 (10-57) 45 (18-78) 51 (18-150) 
FEV1% 
predicted 
(Post BD)† 
113  (86-140) 
99 (78-125) 
(p=0.01)* 
83 (66-102) 
(p<0.001)* 
83 (54-104) 
(p<0.001)* 
FEV1/FVC % 
(Post BD)† 
82 (71-88) 
77 (70-96) 
(p=0.218) 
59 (46-68) 
(p<0.001)* 
57 (38-68) 
p<0.001)* 
Data expressed as median and range. 
NC- Normal control; NLFS-Normal lung function smoker; COPD-CS-COPD 
current smoker; COPD-ES- COPD ex-smoker; N/A-Not any 
*Significance difference from NC  
† Post BD values after 400µg of salbutamol 
‡ Diagnosis of COPD was made according to GOLD 2015 guidelines  
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Legend 
 
Fig-1: Transforming growth factor beta (TGFβ1) - Smad pathway 
 
Fig-2: Comparison of TGFβ1 expression in A) basal epithelial cells B) Rbm cells and 
C) Rbm vessels, between healthy non-smokers (H-N), smokers with normal lung 
function (NLFS), current smoking COPD (S-COPD) and ex-smokers with COPD (ES-
COPD). 
 
Fig-3: Representative photomicrograph of TGFβ1 expression in 4 different study 
group.  
A) Healthy non-smokers (H-N), B) smokers with normal lung function (NLFS), C) 
current smoking COPD (S-COPD) and D) ex-smokers with COPD (ES-COPD). 
Original magnification, ×400. Scale bar =50 µm. 
 
Fig-4: Comparison of phosphorylated (p) Smad 2/3 expression in A) basal epithelial 
cells B) Rbm cells, C) Rbm vessels, D) LP cells, E) as % of LP cells stained and F) 
as number of LP vessels stained. 
 
Fig-5: Photomicrographs of pSmad 2/3 expression representing 4 different study 
groups:  
A) Healthy non-smokers (H-N), B) smokers with normal lung function (NLFS), C) 
current smoking COPD (S-COPD) and D) ex-smokers with COPD (ES-COPD). 
Original magnification, ×400. Scale bar =50 µm. 
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Fig-6: Comparison of phosphorylated (p) Smad 7 expression in A) basal epithelial 
cells B) Rbm cells and C) LP cells. D) LP vessels, in healthy non-smokers (H-N), 
smokers with normal lung function (NLFS), current smoking COPD (S-COPD) and 
ex-smokers with COPD (ES-COPD). 
 
Fig-7: Representative photomicrograph of pSmad 7 expression in 4 different study 
groups:     
A) Healthy non-smokers (H-N), B) smokers with normal lung function (NLFS), C) 
current smoking COPD (S-COPD) and D) ex-smoker with COPD (ES-COPD). 
Original magnification, ×400. Scale bar =50 µm. 
 
Fig-8: Comparison of cellular expression of pSmad 2/3:7 ratio in A) basal epithelial 
cells B) Rbm cells and C) LP cells of healthy non-smokers (H-N), smokers with 
normal lung function (NLFS), current smoking COPD (S-COPD) and ex-smokers 
with COPD (ES-COPD). 
 
Fig-9: A) Correlation between number of basal epithelial cells positive for pSmad 2/3 
and forced expiratory ratio (FER); (B) The same for % predicted FEF25-75 (an index of 
small airway calibre); (C) Correlation between pSmad 7 positive basal epithelial cells 
and FEF 25-75% predicted; (D) Correlation between basal epithelial cell pSmad 2/3:7 
ratio with forced expiratory volume in 1second (FEV1). All these corr lations are for 
the ex-smoker with COPD group (ES-COPD). For pSmad 2/3 there is much higher 
expression with low lung function and increased obstruction, and vice versa with 
pSmad 7. 
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Fig-10: (A) Correlation between number of Rbm cells positive for pSmad 2/3 with 
S100A4 positive Rbm cells; (B) Correlation between number of basal epithelial cells 
positive for pSmad 7 with S100 positive basal cells; (C) Correlation between basal 
epithelial pSmad 2/3:7 ratio with S100A4 positive basal epithelial cells All these 
correlation are also from the ex-smoker COPD group (ES-COPD). 
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Representative photomicrograph of TGFβ1 expression in 4 different study group.  
A) Healthy non-smokers (H-N), B) smokers with normal lung function (NLFS), C) current smoking COPD (S-
COPD) and D) ex-smokers with COPD (ES-COPD). Original magnification, ×400. Scale bar =50 µm.  
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Comparison of phosphorylated (p) Smad 2/3 expression in A) basal epithelial cells B) Rbm cells, C) Rbm 
vessels, D) LP cells, E) as % of LP cells stained and F) as number of LP vessels stained.  
140x68mm (300 x 300 DPI)  
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Photomicrographs of pSmad 2/3 expression representing 4 different study groups:  
A) Healthy non-smokers (H-N), B) smokers with normal lung function (NLFS), C) current smoking COPD (S-
COPD) and D) ex-smokers with COPD (ES-COPD). Original magnification, ×400. Scale bar =50 µm.  
105x60mm (300 x 300 DPI)  
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Comparison of phosphorylated (p) Smad 7 expression in A) basal epithelial cells B) Rbm cells and C) LP 
cells. D) LP vessels, in healthy non-smokers (H-N), smokers with normal lung function (NLFS), current 
smoking COPD (S-COPD) and ex-smokers with COPD (ES-COPD).  
108x60mm (300 x 300 DPI)  
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Representative photomicrograph of pSmad 7 expression in 4 different study groups:      
A) Healthy non-smokers (H-N), B) smokers with normal lung function (NLFS), C) current smoking COPD (S-
COPD) and D) ex-smoker with COPD (ES-COPD). Original magnification, ×400. Scale bar =50 µm.  
105x60mm (300 x 300 DPI)  
 
 
Page 35 of 43
Editorial Office: respirology-aphb@uwa.edu.au; Editor-in-Chief: Prof Peter R. Eastwood
Respirology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
CONFIDENTIAL for peer review only
  
 
 
Comparison of cellular expression of pSmad 2/3:7 ratio in A) basal epithelial cells B) Rbm cells and C) LP 
cells of healthy non-smokers (H-N), smokers with normal lung function (NLFS), current smoking COPD (S-
COPD) and ex-smokers with COPD (ES-COPD).  
108x60mm (300 x 300 DPI)  
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A) Correlation between number of basal epithelial cells positive for pSmad 2/3 and forced expiratory ratio 
(FER); (B) The same for % predicted FEF25-75 (an index of small airway calibre); (C) Correlation between 
pSmad 7 positive basal epithelial cells and FEF 25-75% predicted; (D) Correlation between basal epithelial 
cell pSmad 2/3:7 ratio with forced expiratory volume in 1second (FEV1). All these correlations are for the 
ex-smoker with COPD group (ES-COPD). For pSmad 2/3 there is much higher expression with low lung 
function and increased obstruction, and vice versa with pSmad 7.  
108x60mm (300 x 300 DPI)  
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(A) Correlation between number of Rbm cells positive for pSmad 2/3 with S100A4 positive Rbm cells; (B) 
Correlation between number of basal epithelial cells positive for pSmad 7 with S100 positive basal cells; (C) 
Correlation between basal epithelial pSmad 2/3:7 ratio with S100A4 positive basal epithelial cells All these 
correlation are also from the ex-smoker COPD group (ES-COPD).  
108x60mm (300 x 300 DPI)  
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